Skip to content
RetatrutidevsSemaglutide

Retatrutide vs Semaglutide: Triple Agonist vs the GLP-1 Reference

Semaglutide is the most-cited GLP-1 mono-agonist in metabolic research — the compound behind the STEP obesity programme and the SELECT cardiovascular-outcome trial. Retatrutide activates GLP-1, GIP and glucagon receptors, and its 2023 Phase 2 publication is the main source of published data. Phase 3 trials of Retatrutide are ongoing.

The two literatures answer different questions: Semaglutide is the mono-pathway reference compound, and Retatrutide is a multi-pathway compound. Their pharmacology and research areas differ markedly. LifeSpanSupply lists research reagents for laboratory research use only.

Retatrutide

Class
GLP-1 / GIP / glucagon triple agonist
Half-life
~6 days

Semaglutide

Full entry →
Class
GLP-1 receptor agonist
Half-life
~7 days

Key differences at a glance

PropertyRetatrutideSemaglutide
Receptor targetGLP-1 + GIP + Glucagon (triple)GLP-1 only (mono)
ClassTri-incretin agonistGLP-1 agonist
Half-life (reported)~6 days~7 days
Primary readouts in published trialsBody weight and metabolic markers (Phase 2, 2023)Body weight, HbA1c, cardiovascular events (STEP, SUSTAIN, SELECT)
Published trial breadthPhase 2 published; Phase 3 ongoingSTEP 1–8, SUSTAIN, SELECT — fully mature
Cardiovascular evidenceIn progressSELECT trial reported MACE reduction (2023)

Architectural gap: mono vs triple

Semaglutide activates a single receptor — GLP-1. The downstream effects (insulin secretion, glucagon suppression, delayed gastric emptying, hypothalamic appetite signaling) are well characterized across nearly two decades of literature. The single pathway makes Semaglutide the reference compound for questions that isolate GLP-1 mechanism, without confounders from other incretin pathways.

Retatrutide activates three receptors: GLP-1 (the main incretin pathway), GIP (adipocyte and lipid-handling effects) and glucagon (energy expenditure). Published effect sizes are larger than those reported for mono-agonists, but the multi-pathway architecture means that Retatrutide cannot isolate any single mechanism. The two compounds answer different research questions.

Published trial data

The STEP 1 trial (Wilding et al., 2021, NEJM) reported body-weight change over 68 weeks in adults with overweight or obesity without diabetes. SELECT (Lincoff et al., 2023, NEJM) added a cardiovascular endpoint and reported a significant reduction in major adverse cardiovascular events (MACE).

The Retatrutide Phase 2 trial (Jastreboff et al., 2023, NEJM) reported body-weight change over 48 weeks. No head-to-head trial has been published and the trial durations differ, so the literature does not support a direct ranking. Phase 3 trials are ongoing.

When to pick each

Where the Retatrutide literature focuses

  • The Retatrutide literature is the relevant body when the question concerns glucagon-receptor energy expenditure or multi-receptor signaling.
  • It also provides triple-agonist data for comparison with dual- and mono-agonist reference data.
  • It is the newer literature, based mainly on Phase 2 and mechanism studies.

Where the Semaglutide literature focuses

  • The Semaglutide literature is the relevant body when the longest and most replicated trial record is required (STEP 1–8, SUSTAIN, SELECT).
  • It is also the reference when the question requires GLP-1 mechanism isolation without GIP or glucagon components.
  • It also covers cardiovascular-outcome research, where SELECT is the main reference.

Frequently Asked Questions

Why do Retatrutide trials report larger body-weight changes?

The literature gives two mechanistic reasons: Retatrutide activates three receptors instead of one, and its glucagon component is linked to energy expenditure, a pathway Semaglutide does not engage. No head-to-head trial has been published, so a direct comparison of effect sizes is not possible.

Is Retatrutide FDA-approved?

No — Retatrutide is in Phase 3 trials and is not approved. Semaglutide (as Ozempic / Wegovy) is an FDA-approved medicine for diabetes and weight management. LifeSpanSupply supplies Retatrutide strictly as a research reagent for laboratory use, not for human use.

Shop Retatrutide

All products →

Comparison guides summarize research-context differences. All compounds are chemical reagents for laboratory analysis. See our Terms & Conditions.